

9/C (A312)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Esmond *et al.*

Appl. No. 09/394,712

Filed: September 13, 1999

For: **Method for Treating or
Preventing Alzheimer's Disease**

Art Unit: 1614

Examiner: Kim, V.

Atty. Docket: 0609.4440002

Batch No. A22

RECEIVED

JAN 19 2001

TECH CENTER 1600/2500

Be
1-24-01**Amendment Under 37 C.F.R. § 1.312***Attn: Box Issue Fee*Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herein is an Amendment Under 37 C.F.R. § 1.312. As payment of the issue fee has not yet been made, Applicants respectfully submit that filing under paragraph (a) of 37 C.F.R. § 1.312 is proper. (M.P.E.P. § 714.16.)

Please enter the following Amendment:

In the Claims:

Please amend the claims as follows.

¹⁸
26. (Once amended) The method of claim ¹³20, wherein said [thiazolidinedione] agent is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione.

¹⁹
27. (Once amended) The method of claim ¹³20, wherein said [thiazolidinedione] agent is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxyl]benzyl]thiadiazolidine-2,4-dione hydrochloride.